Jennifer S Gewandter1, William Dale2, Allison Magnuson3, Chintan Pandya4, Charles E Heckler5, Tatyana Lemelman3, Breton Roussel6, Rafa Ifthikhar7, James Dolan4, Katia Noyes8, Supriya G Mohile3. 1. Department of Anesthesiology, University of Rochester, Box 601 Elmwood Ave, Rochester, NY 14642, USA. Electronic address: jennifer_gewandter@urmc.rochester.edu. 2. Section of Geriatrics and Palliative Medicine, University of Chicago, Chicago, IL 60637, USA. 3. James Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA. 4. Department of Public Health Sciences, University of Rochester, Rochester, NY 14642, USA. 5. Department of Surgery, University of Rochester, Rochester, NY 14642, USA. 6. Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08901, USA. 7. Northwestern University, Evanston, IL 60208, USA. 8. Departments Surgery and of Public Health Sciences, University of Rochester, Rochester, NY 14642, USA.
Abstract
OBJECTIVE: In older patients with cancer, we aimed to investigate associations between a patient-reported outcome measure for sarcopenia (SarcoPRO) and the Short Physical Performance Battery (SPPB), self-reported falls, and limitations in instrumental activities of daily living (IADLs). MATERIALS AND METHODS: Assessments were conducted as part of the initial evaluation of older, often frail, patients with cancer seen in the Specialized Oncology Care and Research in the Elderly (SOCARE) clinic. Univariate associations were evaluated using Spearman's correlation and Wilcoxon sign ranked tests. Logistic regressions were used to identify associations of clinical factors and SarcoPRO scores or SPPB scores with falls and IADL limitations. RESULTS: In total, 174 older patients with cancer were evaluated. A moderate correlation was found between the SarcoPRO and the SPPB (ρ=0.62). After adjusting for multiple clinical factors, neither the SarcoPRO nor the SPPB were associated with falls. In contrast, both higher SarcoPRO (i.e., worse) and lower SPPB (i.e., worse) scores were associated with limitations in IADLs (odds ratio for one unit change in predictor: SarcoPRO: 1.06, p<0.0001; SPPB: 0.71, p=0.003, respectively). Models using the SarcoPRO and SPPB explained similar amounts of variability in association with IADL limitations (AUC: 0.88 vs. 0.87, respectively). CONCLUSIONS: The SarcoPRO was moderately associated with the SPPB, an objective measure of physical performance, and was associated with limitations in IADLs. Thus, older patients with cancer who present with IADL limitations should be screened for sarcopenia. The SarcoPRO shows promise as a measure for screening as well as outcome assessment for research on sarcopenia.
OBJECTIVE: In older patients with cancer, we aimed to investigate associations between a patient-reported outcome measure for sarcopenia (SarcoPRO) and the Short Physical Performance Battery (SPPB), self-reported falls, and limitations in instrumental activities of daily living (IADLs). MATERIALS AND METHODS: Assessments were conducted as part of the initial evaluation of older, often frail, patients with cancer seen in the Specialized Oncology Care and Research in the Elderly (SOCARE) clinic. Univariate associations were evaluated using Spearman's correlation and Wilcoxon sign ranked tests. Logistic regressions were used to identify associations of clinical factors and SarcoPRO scores or SPPB scores with falls and IADL limitations. RESULTS: In total, 174 older patients with cancer were evaluated. A moderate correlation was found between the SarcoPRO and the SPPB (ρ=0.62). After adjusting for multiple clinical factors, neither the SarcoPRO nor the SPPB were associated with falls. In contrast, both higher SarcoPRO (i.e., worse) and lower SPPB (i.e., worse) scores were associated with limitations in IADLs (odds ratio for one unit change in predictor: SarcoPRO: 1.06, p<0.0001; SPPB: 0.71, p=0.003, respectively). Models using the SarcoPRO and SPPB explained similar amounts of variability in association with IADL limitations (AUC: 0.88 vs. 0.87, respectively). CONCLUSIONS: The SarcoPRO was moderately associated with the SPPB, an objective measure of physical performance, and was associated with limitations in IADLs. Thus, older patients with cancer who present with IADL limitations should be screened for sarcopenia. The SarcoPRO shows promise as a measure for screening as well as outcome assessment for research on sarcopenia.
Authors: Kim Delbaere; Nele Van den Noortgate; Jan Bourgois; Guy Vanderstraeten; Willems Tine; Dirk Cambier Journal: Clin Rehabil Date: 2006-01 Impact factor: 3.477
Authors: Supriya Gupta Mohile; Ying Xian; William Dale; Susan G Fisher; Miriam Rodin; Gary R Morrow; Alfred Neugut; William Hall Journal: J Natl Cancer Inst Date: 2009-07-28 Impact factor: 13.506
Authors: Benjamin K S Chan; Lynn M Marshall; Kerri M Winters; Kimberly A Faulkner; Ann V Schwartz; Eric S Orwoll Journal: Am J Epidemiol Date: 2006-12-28 Impact factor: 4.897
Authors: Christopher J Evans; Chiun-Fang Chiou; Kristina A Fitzgerald; William J Evans; Betty R Ferrell; William Dale; Linda P Fried; Shravanthi R Gandra; Brooke Dennee-Sommers; Donald L Patrick Journal: J Am Med Dir Assoc Date: 2010-11-25 Impact factor: 4.669
Authors: Martine T E Puts; Johanne Monette; Veronique Girre; Christina Wolfson; Michèle Monette; Gerald Batist; Howard Bergman Journal: Support Care Cancer Date: 2012-09-01 Impact factor: 3.603
Authors: Thuy T Koll; Allison Magnuson; William Dale; Mark A LaBarge; Corinne R Leach; Supriya Mohile; Hyman Muss; Margaret Sedenquist; Heidi D Klepin Journal: J Geriatr Oncol Date: 2019-09-16 Impact factor: 3.599
Authors: Schroder Sattar; Shabbir M H Alibhai; Sandra L Spoelstra; Rouhi Fazelzad; Martine T E Puts Journal: Support Care Cancer Date: 2016-07-22 Impact factor: 3.603
Authors: Ryan D Nipp; Georg Fuchs; Areej El-Jawahri; Julia Mario; Fabian M Troschel; Joseph A Greer; Emily R Gallagher; Vicki A Jackson; Avinash Kambadakone; Theodore S Hong; Jennifer S Temel; Florian J Fintelmann Journal: Oncologist Date: 2017-09-21
Authors: Richard F Dunne; Kah Poh Loh; Grant R Williams; Aminah Jatoi; Karen M Mustian; Supriya G Mohile Journal: Cancers (Basel) Date: 2019-11-25 Impact factor: 6.639
Authors: Sara Hadzibegovic; Philipp Sikorski; Sophia K Potthoff; Jochen Springer; Alessia Lena; Markus S Anker Journal: ESC Heart Fail Date: 2020-10-04